mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response

Abstract

AbstractBackground and AimThe study aims to develop a novel predictive model including the fibrosis (FIB)‐3 index for hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) who achieved sustained virological response (SVR) with direct‐acting antiviral (DAA) therapy.MethodsThis study included 2529 patients in whom HCV was eradicated with DAA therapy. The after DAA recommendation for surveillance (ADRES) score, which is based on sex, FIB‐4 index, and α‐fetoprotein, was used to predict HCC development. We developed a modified ADRES (mADRES) score, in which the FIB‐4 index was replaced by the FIB‐3 index, and evaluated its usefulness in predicting HCC development compared with the ADRES score.ResultsIn the training set (n = 1770), multivariate analysis with Cox proportional hazards modeling showed that male sex (hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.48–3.01), FIB‐3 index (HR, 1.36; 95% CI, 1.28–1.45), and α‐fetoprotein (HR, 1.05; 95% CI, 1.03–1.07) are independently associated with HCC development. The incidence of HCC differed significantly by ADRES or mADRES score in multiple comparisons. Univariate Cox proportional hazards models showed that compared with the mADRES score 0 group, the HR for HCC development was 2.07 (95% CI, 1.02–4.19) for the mADRES score 1 group, 11.37 (95% CI, 5.80–22.27) for the mADRES score 2 group, and 21.95 (95% CI, 10.17–47.38) for the mADRES score 3 group. Similar results were obtained for mADRES score but not for ADRES score in the validation set (n = 759).ConclusionThe mADRES score is useful for predicting HCC development after SVR.